Literature DB >> 15271908

Immunostimulatory CpG oligodeoxynucleotide confers protection in a murine model of infection with Burkholderia pseudomallei.

Surasakdi Wongratanacheewin1, Wannapa Kespichayawattana, Pakamas Intachote, Sathit Pichyangkul, Rasana W Sermswan, Arthur M Krieg, Stitaya Sirisinha.   

Abstract

Although CpG oligodeoxynucleotides (CpG ODNs) are known to enhance resistance against infection in a number of animal models, little is known about the CpG-induced protection against acute fatal sepsis such as that associated with the highly virulent bacterium Burkholderia pseudomallei. We previously demonstrated in an in vitro study that immunostimulatory CpG ODN 1826 enhances phagocytosis of B. pseudomallei and induces nitric oxide synthase and nitric oxide production by mouse macrophages. In the present study, CpG ODN 1826 given intramuscularly to BALB/c mice 2 to 10 days prior to B. pseudomallei challenge conferred better than 90% protection. CpG ODN 1826 given 2 days before the bacterial challenge rapidly enhanced the innate immunity of these animals, judging from the elevated serum levels of interleukin-12 (IL-12)p70 and gamma interferon (IFN-gamma) over the baseline values. No bacteremia was detected on day 2 in 85 to 90% of the CpG-treated animals, whereas more than 80% of the untreated animals exhibited heavy bacterial loads. Although marked elevation of IFN-gamma was found consistently in the infected animals 2 days after the bacterial challenge, it was ameliorated by the CpG ODN 1826 pretreatment (P = 0.0002). Taken together, the kinetics of bacteremia and cytokine profiles presented are compatible with the possibility that protection by CpG ODN 1826 against acute fatal septicemic melioidosis in this animal model is associated with a reduction of bacterial load and interference with the potential detrimental effect of the robust production of proinflammatory cytokines associated with B. pseudomallei multiplication.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15271908      PMCID: PMC470634          DOI: 10.1128/IAI.72.8.4494-4502.2004

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  45 in total

Review 1.  CpG DNA: trigger of sepsis, mediator of protection, or both?

Authors:  Arthur M Krieg
Journal:  Scand J Infect Dis       Date:  2003

Review 2.  Proinflammatory cytokines and sepsis syndrome: not enough, or too much of a good thing?

Authors:  Mihai G Netea; Jos W M van der Meer; Marcel van Deuren; Bart Jan Kullberg
Journal:  Trends Immunol       Date:  2003-05       Impact factor: 16.687

3.  Matching SOCS with function.

Authors:  James A Johnston; John J O'Shea
Journal:  Nat Immunol       Date:  2003-06       Impact factor: 25.606

4.  Elevated plasma concentrations of interferon (IFN)-gamma and the IFN-gamma-inducing cytokines interleukin (IL)-18, IL-12, and IL-15 in severe melioidosis.

Authors:  F N Lauw; A J Simpson; J M Prins; M D Smith; M Kurimoto; S J van Deventer; P Speelman; W Chaowagul; N J White; T van der Poll
Journal:  J Infect Dis       Date:  1999-12       Impact factor: 5.226

5.  Immune cell activation in melioidosis: increased serum levels of interferon-gamma and soluble interleukin-2 receptors without change in soluble CD8 protein.

Authors:  A E Brown; D A Dance; Y Suputtamongkol; W Chaowagul; S Kongchareon; H K Webster; N J White
Journal:  J Infect Dis       Date:  1991-05       Impact factor: 5.226

6.  Distinct modulatory effects of LPS and CpG on IL-18-dependent IFN-gamma synthesis.

Authors:  Meetha P Gould; Jennifer A Greene; Vijay Bhoj; Jennifer L DeVecchio; Frederick P Heinzel
Journal:  J Immunol       Date:  2004-02-01       Impact factor: 5.422

7.  Involvement of beta interferon in enhancing inducible nitric oxide synthase production and antimicrobial activity of Burkholderia pseudomallei-infected macrophages.

Authors:  P Utaisincharoen; N Anuntagool; K Limposuwan; P Chaisuriya; S Sirisinha
Journal:  Infect Immun       Date:  2003-06       Impact factor: 3.441

Review 8.  Melioidosis.

Authors:  N J White
Journal:  Lancet       Date:  2003-05-17       Impact factor: 79.321

Review 9.  Interleukin-18 and host defense against infection.

Authors:  Charles A Dinarello; Giamila Fantuzzi
Journal:  J Infect Dis       Date:  2003-06-15       Impact factor: 5.226

10.  Obligatory role of gamma interferon for host survival in a murine model of infection with Burkholderia pseudomallei.

Authors:  P Santanirand; V S Harley; D A Dance; B S Drasar; G J Bancroft
Journal:  Infect Immun       Date:  1999-07       Impact factor: 3.441

View more
  26 in total

1.  Bacterial loads and antibody responses in BALB/c mice infected with low and high doses of Burkholderia pseudomallei.

Authors:  Nuttiya Srisurat; Rasana W Sermswan; Unchalee Tatawasart; Surasakdi Wongratanacheewin
Journal:  Am J Trop Med Hyg       Date:  2010-06       Impact factor: 2.345

2.  Immunotherapy markedly increases the effectiveness of antimicrobial therapy for treatment of Burkholderia pseudomallei infection.

Authors:  Katie L Propst; Ryan M Troyer; Lisa M Kellihan; Herbert P Schweizer; Steven W Dow
Journal:  Antimicrob Agents Chemother       Date:  2010-02-22       Impact factor: 5.191

3.  Role of TLR signaling in Francisella tularensis-LPS-induced, antibody-mediated protection against Francisella tularensis challenge.

Authors:  Leah E Cole; Barbara J Mann; Kari Ann Shirey; Katharina Richard; Yang Yang; Patricia J Gearhart; Kirsty L Chesko; Rose M Viscardi; Stefanie N Vogel
Journal:  J Leukoc Biol       Date:  2011-07-12       Impact factor: 4.962

4.  CpG oligodeoxyribonucleotides protect mice from Burkholderia pseudomallei but not Francisella tularensis Schu S4 aerosols.

Authors:  David A Rozak; Herbert C Gelhaus; Mark Smith; Mojgan Zadeh; Louis Huzella; David Waag; Jeffrey J Adamovicz
Journal:  J Immune Based Ther Vaccines       Date:  2010-02-05

5.  Cationic liposomes extend the immunostimulatory effect of CpG oligodeoxynucleotide against Burkholderia pseudomallei infection in BALB/c mice.

Authors:  Apichaya Puangpetch; Robert Anderson; Yan Y Huang; Rasana W Sermswan; Wanpen Chaicumpa; Stitaya Sirisinha; Surasakdi Wongratanacheewin
Journal:  Clin Vaccine Immunol       Date:  2012-03-21

Review 6.  Targeting the "cytokine storm" for therapeutic benefit.

Authors:  Riccardo V D'Elia; Kate Harrison; Petra C Oyston; Roman A Lukaszewski; Graeme C Clark
Journal:  Clin Vaccine Immunol       Date:  2013-01-02

Review 7.  Melioidosis: epidemiology, pathophysiology, and management.

Authors:  Allen C Cheng; Bart J Currie
Journal:  Clin Microbiol Rev       Date:  2005-04       Impact factor: 26.132

8.  Protection from pneumonic infection with burkholderia species by inhalational immunotherapy.

Authors:  Andrew Goodyear; Lisa Kellihan; Helle Bielefeldt-Ohmann; Ryan Troyer; Katie Propst; Steven Dow
Journal:  Infect Immun       Date:  2009-01-29       Impact factor: 3.441

9.  CpG-modified plasmid DNA encoding flagellin improves immunogenicity and provides protection against Burkholderia pseudomallei infection in BALB/c mice.

Authors:  Yao-Shen Chen; Yu-Shan Hsiao; Hsi-Hsun Lin; Yin Liu; Ya-Lei Chen
Journal:  Infect Immun       Date:  2006-03       Impact factor: 3.441

10.  A CpG oligonucleotide can protect mice from a low aerosol challenge dose of Burkholderia mallei.

Authors:  David M Waag; Michael J McCluskie; Ningli Zhang; Arthur M Krieg
Journal:  Infect Immun       Date:  2006-03       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.